- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- NeuroMab™ Anti-Tau Antibody,Clone NR2218P (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-GD2 Antibody,Clone NR3007P (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- NeuroMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- NeuroMab™ Anti-GARP Antibody,Clone NR3348P (Cat#: NRP-0422-P1639)
- NeuroMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody,Clone NR2431P (Cat#: NRZP-1222-ZP1218)
- NeuroMab™ Anti-pTau Antibody,Clone NR3595P (Cat#: NRP-0422-P1719)
- NeuroMab™ Anti-SEZ6 Antibody, Clone NR28P (Cat#: NRP-0422-P515)
- NeuroMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- C57 Brain Cortex Neurons [Mouse] (Cat#: NCC20-9PZ48)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Hippocampal Neuron Cells HPPNCs (Cat#: NCL2110P106)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- iNeu™ Human Midbrain Dopaminergic Neurons (Cat#: NCL-21P6-003)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit, TTF Assay (Cat#: NRZP-0323-ZP199)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- pAAV-syn-FLEX-jGCaMP8m-WPRE (Cat#: NTA-2106-P065)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- AAV2/9-hSyn-Flpo-EGFP-WPRE-pA (Cat#: NTA-2012-ZP149)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- AAV2/2Retro-CAG-DIO-EGFP-2A-TetTox-pA [Neural Tracing] (Cat#: NTA-2012-ZP303)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- AAV-EF1a-mCherry-flex-dtA (Cat#: NRZP-0622-ZP616)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- ABCA1 Antisense Oligonucleotide (AK311445) (Cat#: NV-2106-P27)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein, cTfRMAb-EPO (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein, 8D3-IL-1RA (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein, cTfRMAb-GDNF (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein, HIRMab-IDUA (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-IDS BBB Shuttle Protein, HIRMab-IDS (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein, cTfRMAb-IDUA (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein, HIRMab-PON1 (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein, HIRMab-TNFR (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein, cTfRMAb-TNFR (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-ASA BBB Shuttle Protein, HIRMab-ASA (Cat#: NRZP-0423-ZP504)
Migraine Headache Drug Discovery Service
Creative Biolabs has accumulated years of experience in the life sciences. We offer a full range of customized one-stop solutions to meet your research needs in neuroscience to be addressed, facilitating the process of migraine headache research from mechanistic to clinical translational studies. Our experienced scientists will customize our solutions to meet your research needs and answer any questions you may have.
Background of Migraine Headache
Migraine headache is a complex neurological disorder producing a series of neurological and systemic symptoms, including inflammation, alterations in the vasculature, as well as central and peripheral pain processing. The migraineurs are heterogeneous, thus spawning continued advances in migraine research to identify promising new treatment targets for migraine headaches. According to different mechanisms of action in the induction and maintenance of migraine headaches, divergent classes of drugs are used to regulate the state of the migraine, such as anticonvulsants, tricyclic antidepressants, anti-calcitonin gene-related peptides (CGRP), etc. Due to the limitation of those drugs, a range of novel therapeutics for migraine is being developed. Creative Biolabs has established a pain research platform, which enables researchers to understand the mechanism of action in migraine headaches as well as to have an opportunity to discover novel drug targets and screen drug compounds more effectively.
Emerging Therapeutic Targets for Migraine Headache
Emerging therapeutic targets for migraine headaches have garnered attention in recent years, including pituitary adenylate cyclase-activating protein (PACAP), nitric oxide (NO)-based therapies, the δ, and κ opioid receptors, and orexin (Bertels, 2019). In addition, there are emerging therapeutics targeting cyclic adenosine monophosphate (cAMP) system, membrane hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, and glutamate or kynurenate. Thanks to the cross expertise of our platforms, Creative Biolabs provides a full range of combinations to assist our clients to explore potential therapeutic targets for migraine headaches.
Fig.1 Current view of migraine pathophysiology and potential mechanisms of available specific treatments. (Haanes, 2019)
Migraine Headache Solutions at Creative Biolabs
It is emphasized that understanding the distinct types of migraine signaling pathways can lead to more targeted preclinical drug development and a better chance of success. Creative Biolabs is a well-recognized one-stop solution provider, offering discovery services for migraine headaches. Besides, we also provide a broad range of in vitro, in vivo, and ex vivo assays in neural research with advanced tools and platforms and suitable cell culture and animal models, such as neuronal cultures, spinal cord slices, iPSC-derived sensory neurons, and anaesthetized mice. You can find any professional services associated with migraine headaches at Creative Biolabs, enabling an optimal understanding of the mechanisms of action in migraine headaches, and thus meet your research and development requirements to develop novel targeting therapeutics. You can find more detailed information about our platform and services for translational research and integrated research in migraine headaches with the following scheme.
If you want to learn more about our one-stop solutions for preclinical migraine headaches drug discovery, please don't hesitate to contact us.
References
- Bertels, Z.; Pradhan, A. A. A. Emerging treatment targets for migraine and other headaches. Headache: The Journal of Head and Face Pain. 2019, 59: 50-65.
- Haanes, K. A.; Edvinsson, L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS drugs. 2019, 33(6): 525-537.